Table 4 Univariate analysis with respect to DFS and OS in 118 patients with invasive breast cancer
From: NHERF1 and tumor microenvironment: a new scene in invasive breast carcinoma
DFS | OS | |||||||
|---|---|---|---|---|---|---|---|---|
Characteristics | No. pts. | events | 5-year DFS (95% CI)a | HR (95% CI)b | p-value c | events | 5-year OS (95% CI)a | p-value c |
Overall | 118 | 37 | 83 (76, 91) | 2 | 98 (95, 100) | |||
Age | ||||||||
≤ 49 | 74 | 23 | 84 (75, 94) | 1.00 | 0.993 | 2 | 97 (92, 100) | 0.275 |
> 49 | 44 | 14 | 81 (69, 95) | 1.00 (0.51 1.94) | 0 | 100 (100, 100) | ||
cNHERF1 | ||||||||
Negative (< 40%) | 48 | 16 | 83 (72, 95) | 1.00 | 0.546 | 2 | 95 (89, 100) | 0.150 |
Positive (≥ 40%) | 49 | 15 | 85 (75, 97) | 0.80 (0.40, 1.63) | 0 | 100 (100, 100) | ||
nNHERF1 | ||||||||
Negative (0%) | 81 | 28 | 83 (74, 92) | 1.00 | 0.382 | 2 | 97 (93, 100) | 0.547 |
Positive (> 0%) | 16 | 3 | 92 (77, 100) | 0.59 (0.18, 1.95) | 0 | 100 (100, 100) | ||
mNHERF1 | ||||||||
Negative (0%) | 86 | 26 | 85(77, 94) | 1.00 | 0.133 | 2 | 97 (94, 100) | 0.642 |
Positive (> 0%) | 13 | 5 | 75 (50, 100) | 2.06 (0.79, 5.42) | 0 | 100 (100, 100) | ||
cVEGF | ||||||||
Negative (0–2) | 44 | 12 | 76 (62, 92) | 1.00 | 0.632 | 1 | 97 (90, 100) | 0.742 |
Positive (3–7) | 56 | 19 | 88 (79, 97) | 0.84 (0.41, 1.73) | 1 | 98 (95, 100) | ||
cVEGFR1 | ||||||||
Negative (0%) | 50 | 16 | 83 (73, 95) | 1.00 | 0.427 | 1 | 97 (92, 100) | 0.930 |
Positive (> 0%) | 56 | 15 | 87 (78, 97) | 0.75 (0.37, 1.52) | 1 | 98 (94, 100) | ||
MVD | ||||||||
Negative (< 15microvessels/mm2) | 42 | 14 | 82 (70, 95) | 1.00 | 0.541 | 2 | 95 (88, 100) | 0.111 |
Positive (≥ 15microvessels/mm2) | 58 | 16 | 89 (80, 98) | 0.80 (0.39, 1.64) | 0 | 100 (100, 100) | ||
nHIF-1α | ||||||||
Negative (0%) | 62 | 18 | 85 (75, 95) | 1.00 | 0.813 | 2 | 96 (91, 100) | 0.270 |
Positive (> 0%) | 39 | 11 | 91 (81, 700) | 0.91 (0.43, 1.94) | 0 | 100 (100, 100) | ||
nTWIST1 | ||||||||
Negative (4%) | 46 | 20 | 77 (65, 91) | 1.00 | < 0.001 | 1 | 97 (92, 100) | 0.304 |
Positive (> 4%) | 47 | 8 | 92 (85, 100) | 0.25 (0.10, 0.58) | 0 | 100 (100, 100) | ||
Hystological type | ||||||||
CDI | 105 | 32 | 84 (77, 92) | 1.00 | 0.476 | 2 | 98 (95, 100) | 0.894 |
CLI | 9 | 4 | 59 (92, 100) | 1.83 (0.64, 5.18) | 0 | 100 (100, 100) | ||
Other | 4 | 1 | 100 (100, 100) | 0.72 (0.10, 5.25) | 0 | 100 (100, 100) | ||
Hystological grade | ||||||||
G1 | 14 | 4 | 91 (75, 100) | 1.00 | 0.874 | 0 | 100 (100, 100) | 0.240 |
G2 | 53 | 17 | 83 (73, 94) | 1.30 (0.44, 3.88) | 0 | 100 (100, 100) | ||
G3 | 51 | 16 | 81 (70, 94) | 0.32 (0.44, 3.97) | 2 | 95 (89, 100) | ||
Tumor size (cm) | ||||||||
≤ 2 cm | 44 | 14 | 93 (85, 100) | 1.00 | 0.675 | 0 | 100 (100, 100) | 0.242 |
> 2 cm | 72 | 21 | 80 (69, 90) | 1.16 (0.59, 2.28) | 2 | 97 (92, 100) | ||
Receptor status | ||||||||
ER-Negative (≤ 10%) | 38 | 10 | 80 (68, 96) | 1.00 | 0.675 | 2 | 94 (85, 100) | 0.033 |
ER-Positive (> 10%) | 80 | 27 | 84 (76, 93) | 1.16 (0.56, 2.42) | 0 | 100 (100, 100) | ||
PgR-Negative (≤ 10%) | 47 | 18 | 76 (64, 90) | 1.00 | 0.193 | 2 | 95 (89, 100) | 0.092 |
PgR-Positive (> 10%) | 71 | 19 | 88 (80, 97) | 0.65 (0.34, 1.25) | 0 | 100 (100, 100) | ||
MIB-1 | ||||||||
Negative (≤ 20%) | 47 | 7 | 87 (77, 98) | 1.00 | 0.003 | 1 | 97 (92, 100) | 0.773 |
Positive (> 20%) | 71 | 30 | 80 (71, 91) | 3.20 (1.40, 7.30) | 1 | 98 (96, 100) | ||
HER2/neu | ||||||||
Negative (0/+ 1) | 59 | 19 | 88 (79, 98) | 1.00 | 0.780 | 0 | 100 (100, 100) | 0.098 |
Positive (+3) | 45 | 13 | 75 (61, 90) | 1.11 (0.55, 2.24) | 2 | 94 (87, 100) | ||